Centessa Pharmaceuticals (NASDAQ:CNTA) Sees Large Volume Increase – What’s Next?

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) shares saw unusually-strong trading volume on Thursday . 1,975,302 shares traded hands during trading, a decline of 5% from the previous session’s volume of 2,074,203 shares.The stock last traded at $39.8250 and had previously closed at $39.87.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the stock. Guggenheim downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Monday, April 20th. Truist Financial downgraded shares of Centessa Pharmaceuticals from a “buy” rating to a “hold” rating and set a $38.00 price target for the company. in a research note on Monday, April 13th. Wells Fargo & Company lowered shares of Centessa Pharmaceuticals from an “overweight” rating to an “equal weight” rating and upped their price objective for the company from $35.00 to $42.00 in a report on Monday, April 20th. Finally, Leerink Partners lowered shares of Centessa Pharmaceuticals from an “outperform” rating to a “hold” rating and upped their price objective for the company from $36.00 to $40.00 in a report on Wednesday, April 1st. Four research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Centessa Pharmaceuticals has an average rating of “Hold” and an average target price of $41.33.

Centessa Pharmaceuticals Stock Performance

The company’s 50 day moving average price is $39.67 and its 200-day moving average price is $31.25. The stock has a market cap of $6.19 billion, a P/E ratio of -22.36 and a beta of 1.11. The company has a debt-to-equity ratio of 0.23, a quick ratio of 9.53 and a current ratio of 9.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, May 5th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.14). Equities analysts forecast that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.65 EPS for the current fiscal year.

Insider Transactions at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 41,076 shares of the stock in a transaction on Thursday, March 26th. The stock was sold at an average price of $30.12, for a total transaction of $1,237,209.12. Following the sale, the insider owned 62,085 shares in the company, valued at $1,870,000.20. This represents a 39.82% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 4.09% of the stock is owned by insiders.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several hedge funds have recently made changes to their positions in the stock. TD Waterhouse Canada Inc. purchased a new stake in Centessa Pharmaceuticals during the 4th quarter worth about $25,000. Caitong International Asset Management Co. Ltd purchased a new position in Centessa Pharmaceuticals during the 4th quarter valued at about $36,000. T. Rowe Price Investment Management Inc. increased its position in shares of Centessa Pharmaceuticals by 7,580.0% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock valued at $39,000 after buying an additional 1,516 shares during the period. Wells Fargo & Company MN increased its position in shares of Centessa Pharmaceuticals by 42.4% during the fourth quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock valued at $85,000 after buying an additional 1,008 shares during the period. Finally, Knott David M Jr bought a new position in shares of Centessa Pharmaceuticals in the fourth quarter valued at approximately $100,000. 82.01% of the stock is currently owned by hedge funds and other institutional investors.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.